VR Logo

Fate Therapeutics Inc. (FATE) download report


Healthcare | Biotechnology & Pharma Research

Fate Therapeutics Inc. (FATE) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.

IPO Date: 01-Oct-2013

Founder, CEO, Pres & Director: Mr. J. Scott Wolchko

Chief Financial Officer: Mr. Edward J. Dulac III

Listing: NASDAQ: FATE

Country: United States

Headquarters: San Diego, CA

Website: https://www.fatetherapeutics.com

Key Facts

Market cap: $2,536.51 Mln

Revenue (TTM): $63.12 Mln

Earnings (TTM): $-232.75 Mln

Cash: $573.77 Mln

Total Debt: $113.52 Mln

Insider's Holding: 1.42%

Liquidity: Low

52 Week range: $17.11 - 97.43

Shares outstanding: 96,629,104

10 Years Aggregate:

  • CFO: $-460.12 Mln
  • EBITDA: $-687.87 Mln
  • Net Profit: $-717.71 Mln

Stock Performance

Time Period Fate Therapeutics (FATE) S&P BSE Sensex* S&P Small-Cap 600*
YTD-57.70-8.97-18.40
1 month4.96-3.38-8.42
3 months-34.87-7.93-14.06
1 Year-70.730.55-17.64
3 Years6.5910.416.75
5 Years50.8411.456.18
10 Years--12.0510.23
As on 28-Jun-2022 *As on 29-Jun-2022
Year Fate Therapeutics (FATE) S&P Small-Cap 600 S&P BSE Sensex
2021-35.6525.2721.99
2020364.649.5715.75
201952.5320.8614.38
2018109.14-9.705.87
2017143.4311.7327.91
2016-25.5224.741.95
2015-33.00-3.36-5.03